Navigation Links
ERT Reports First Quarter 2009 Results
Date:4/30/2009

as $157.0 million as of March 31, 2009 compared to $151.4 million a year ago. The annualized cancellation rate was 22.4% in the first quarter of 2009 compared to 19.3% in the fourth quarter of 2008 and 15.6% in the first quarter of 2008.

"The results for this quarter were in line with our expectations, as given by our guidance in February," commented Dr. Michael McKelvey, President and CEO of ERT. "The first quarter was marked by a significant decline in revenue, in large part due to a sharp reduction in Thorough QT revenue. This reflects the ability of companies to delay the running of Thorough QT trials until later in the drug development cycle, though current regulatory guidance ultimately requires that they be performed. Routine revenue (Phase I through Phase IV trials) was also impacted as a result of the larger percentage of our past business being booked in Phase III trials, which are longer-term trials and thus take longer to turn into revenue, as well as a slower rate of spending by our pharmaceutical and biotechnology clients. The latter reflects the current difficult economic environment and the uncertainty seen in pharmaceutical sponsors' spending. Despite the revenue decline, our gross margin percentage remained above 50%. We continue to be pleased with our strong operational performance and with the results of our discussions with key pharmaceutical and biotechnology companies on strategic outsourcing relationships."

"We made good progress on our strategic priorities in the first quarter," continued Dr. McKelvey. "We continue to be successful in winning new and expanded exclusive or near-exclusive long-term enterprise partnerships with large clients, which should positively impact our future levels of new booking activity. We successfully launched two significant efforts aimed at expanding industry penetration of centralized ECGs by focusing on how centralization of ECGs ca
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. Caliper Life Sciences Reports First Quarter 2009 Results
3. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Telik Reports Preclinical Results at AACR Annual Meeting
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
10. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 Lawrence Livermore ... to Thomson Reuters list of " The World's Most ... part of the 3,000 researchers who were identified by ... recognize those who published the highest-impact work (2002-2012 and ... papers on combustion modeling . , "This recognition ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... gradual extinction of cold-loving species, and the European land ... from the University of Kassel in Germany and the ... that human-induced temperature increases over a 40-year period in ... the near extinction of the local land leech Xerobdella ...
... have long known that the human body runs like clockwork, ... of light and darkness. Now a team of researchers is ... activity, which could allow them to predict optimal timing for ... solar day and relieve psychosocial stress. In short, ...
... showing that dog-walking in bushland significantly reduces bird ... against the practice in sensitive bushland and conservation ... the ecological impacts of dog-walking have remained subjective ... But the first clear evidence that birds ...
Cached Biology News:Role reversal as humans suck life out of leeches 2Researchers developing device to predict proper light exposure for human health 2Researchers developing device to predict proper light exposure for human health 3A dog in the hand scares birds in the bush 2
...
...
... White solid. PROTECT FROM LIGHT. ... sulfanamido-benzbromarone compound that acts as a ... of PTP1B (IC 50 = ... PTP1B 403 and PTP1B 298 ...
...
Biology Products: